ArticleScientific reports2026
Myricetin alleviates testosterone-induced benign prostatic hyperplasia by attenuating inflammation, oxidative stress, apoptosis and androgen signaling.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The interplay of bosentan and finerenone in amelioration of cardiac dysfunction within benign prostatic hyperplasia in rats.Molecular biology reports · 2026Article
- Endoplasmic reticulum-mitochondria contact sites in benign prostatic hyperplasia: evidence integration and mechanistic hypotheses.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
This study investigates the effect of myricetin as a therapeutic for benign prostatic hyperplasia (BPH) disease using a testosterone-induced BPH animal model. Forty adult male rats were randomly divided into four groups as follows: control group, BPH group that was injected with testosterone subcutaneously (3 mg/kg body weight/day), BPH + myricetin group, which received myricetin (50 mg/kg) subcutaneously every day with the BPH induction, and BPH + finasteride group, which administered finasteride orally with the BPH induction at a daily dose of 5 mg/kg. After 28 days, blood and prostate tissue samples were collected for analysis. Compared to the control group, treatment with myricetin improved the pathohistological signs of BPH and enhanced the antioxidant and anti-inflammatory capacity of the prostatic tissue, as evidenced by its ability to enhance the total antioxidant capacity (TAC) levels and reduce malondialdehyde (MDA) levels, decrease the levels of the inflammatory biomarkers tumor necrosis factor alpha (TNF-α) and interleukin-1 beta (IL1-β) levels, and reduce serum dihydrotestosterone (DHT) levels. In addition, myricetin treatment showed beneficial effects through its ability to reduce the prostatic mRNA expression levels of the anti-apoptotic protein Bcl2, the 5-α reductase enzyme, and the androgen receptor (AR), while simultaneously increasing the prostatic mRNA expression levels of the pro-apoptotic protein Bax. Myricetin treatment also exhibited anti-proliferative and anti-angiogenic effects, as evidenced by the reduced prostatic proliferating cell nuclear antigen (PCNA) and vascular endothelial growth factor-A (VEGF-A) mRNA expression levels. In summary, myricetin displays potential as a BPH therapy by diminishing inflammation and oxidative stress, hindering 5-α reductase/AR/DHT signaling, and endorsing pro-apoptotic over anti-apoptotic pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.